Cabergoline for Lactation Inhibition After Abortion
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:
Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?
Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?
Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.
Participants will:
Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure
Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure
Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother
A subset of participants will provide blood samples at selected time points to measure serum prolactin levels
Who Is on the Research Team?
June Ng, MD
Principal Investigator
Maimonides Medical Canter
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure
Treatment
Participants receive a single oral dose of either cabergoline or placebo approximately one hour after the procedure
Follow-up
Participants complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother
Optional Blood Sampling
A subset of participants provide blood samples at selected time points to measure serum prolactin levels
What Are the Treatments Tested in This Trial?
Interventions
- Cabergoline
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation will receive a single 1 mg oral dose of Cabergoline approximately one hour after the procedure. Participants will complete baseline and follow-up surveys assessing breast symptoms, including breast engorgement, milk leakage, tenderness, and need for pain relief, at multiple time points through 14 days after the procedure. A subset of participants may also provide blood samples for measurement of serum prolactin levels.
Participants undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation will receive a single oral dose of placebo approximately one hour after the procedure. Participants will complete baseline and follow-up surveys assessing breast symptoms, including breast engorgement, milk leakage, tenderness, and need for pain relief, at multiple time points through 14 days after the procedure. A subset of participants may also provide blood samples for measurement of serum prolactin levels.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Maimonides Medical Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.